Healthleap raises $38 million to flag hospital patients

Healthleap has raised 38 million dollars to widen a hospital tool that reads patient records and marks people who may need a closer look. TechCrunch reported the figure on 7 October 2026. An 8 million dollar seed round was co-led by Sequoia Capital and First Round Capital. A 30 million dollar Series A was led by Hummingbird Ventures. The company did not publish a valuation. The tool does not make a diagnosis. It pulls notes, lab results and vital signs, then writes a risk score into the ward’s workflow by the next morning, with a short view of what changed. The conditions in daily use, the company says, are malnutrition and delirium. Programs for aspiration pneumonia, pressure ulcers and the chance of a heart-failure patient coming back are still in clinical checks. Chief executive Josiah Meyer said the new money will go to engineering, product, sales and customer support, and that the aim is to cover more than 40 conditions, then outpatient and home care. Meyer and his sister Jemima founded the company in South Africa in 2022. It began as a nutrition tool Jemima had built for dieticians. It now says it is in more than 50 hospitals, up from three a year ago. Named customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Meyer said revenue grew more than tenfold in that year and did not give the number. Contracts run three years and are priced on licensed beds, with a second model tied to results. He said every customer so far has seen at least a fivefold return, and some more than twentyfold. That is his figure. The only hospital sum in the notes is from the Hospital of the University of Pennsylvania. Healthleap says its malnutrition program produced 23.8 million dollars of annual effect: 6.3 million from extra reimbursement and 17.5 million from shorter stays. A separate line, carried in the company’s own announcement, said flagged patients left 1.6 days sooner, and that Cedars-Sinai recorded 39 percent more appropriate diagnoses with the same staff. A 2025 study of the malnutrition screen covered one hospital. It did not test the other conditions. A case study is not a trial. For hospital managers in the Gulf, the useful question is not the label on the software. Riyadh and Abu Dhabi are buying record systems and early-warning scores at the same time as they add beds. A tool that starts from nutrition, a problem already coded in billing, is easier to defend to a finance committee than a general alert. It is also easier to over-claim. If a Saudi or Emirati group signs, the test is whether the shorter stay shows up in that hospital’s own discharge data, not in a Philadelphia case study. The round is real. The reach is company-reported. Valuation, revenue and the return multiple are not in a filing. Conditions beyond malnutrition and delirium are not yet cleared by a published study. The software flags. A clinician still has to act. If Healthleap names a second hospital with its own audited stay and reimbursement numbers, the Pennsylvania figure travels. If the next note is only a longer list of conditions, count wards where a nurse opened the score. The number to ask for is the stay, in days, at the buyer’s own site.